神经调控患者术前凝血状态评估
该研究回顾了9年间接受神经调控(脊髓电刺激、脑深部电刺激或鞘内泵植入)且术前有实验室检查值的1767例患者,其中136例术前实验室值异常。作者发现新型抗凝药和抗血小板药虽不通过凝血酶原时间/部分凝血活酶时间监测,但会影响凝血状态和实验室值,凝血酶原时间/部分凝血活酶时间可能提供术前价值。
要点
- 神经调控患者术前凝血异常需结合临床方案判断,本研究方案凝血酶原时间 cutoff 为12秒、部分凝血活酶时间为39秒、血小板<120,000/μl。
- 136例术前实验室值异常患者中,48例正在使用其他抗凝/抗血小板药物,包括阿哌沙班/利伐沙班/达比加群(n=22)和阿司匹林/氯吡格雷/其他抗血小板药(n=26)。
- 作者认为凝血酶原时间/部分凝血活酶时间可能在术前提供价值,但新型抗凝药患者的凝血状态评估较困难。
核心结论
- 新型抗凝药和抗血小板药物不通过凝血酶原时间/部分凝血活酶时间监测,但会影响凝血状态和实验室值。
- 尽管血小板功能试验对部分药物有帮助,但接受新型抗凝药患者的凝血状态评估更为困难。
- 凝血酶原时间/部分凝血活酶时间可能在术前提供价值。
研究设计与样本
- 回顾性纳入9年间接受神经调控(脊髓电刺激、脑深部电刺激或鞘内泵植入)且术前有实验室检查值的患者,共1767例符合标准。
- 根据本研究中心采用的临床方案判定异常值,该方案结合实验室正常范围和临床相关性,凝血酶原时间 cutoff 为12秒、部分凝血活酶时间为39秒、血小板<120,000/μl。
- 识别这些异常的危险因素并描述干预措施。
主要发现
- 1767例患者中136例术前实验室值异常。
- 136例中5例因在外院检测时处于正常范围而被误判为异常。
- 51例实验室值超出本方案范围,但外科医生审查后批准手术而未进一步干预。
- 剩余80例中,8例有已知凝血病,24例正在使用华法林/肝素。
- 剩余48例正在使用其他抗凝/抗血小板药物:阿哌沙班/利伐沙班/达比加群(n=22;平均±标准差凝血酶原时间13.7±2.5秒)和阿司匹林/氯吡格雷/其他抗血小板药(n=26;平均±标准差凝血酶原时间14.4±5.8秒);新发现8例凝血病并进一步行血液学分析。
关键数值与推荐
- 本研究临床方案判定异常值的 cutoff:凝血酶原时间12秒、部分凝血活酶时间39秒、血小板<120,000/μl。
- 接受阿哌沙班/利伐沙班/达比加群的患者(n=22)平均±标准差凝血酶原时间为13.7±2.5秒。
- 接受阿司匹林/氯吡格雷/其他抗血小板药的患者(n=26)平均±标准差凝血酶原时间为14.4±5.8秒。
临床怎么用
- 作者认为凝血酶原时间/部分凝血活酶时间可能在术前提供价值。
- 作者指出新型抗凝药和抗血小板药物不通过凝血酶原时间/部分凝血活酶时间监测,但影响凝血状态和实验室值。
- 作者指出接受新型抗凝药患者的凝血状态评估更为困难,尽管血小板功能试验对部分药物有帮助。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The incidence of hemorrhage in patients who undergo deep brain stimulation (DBS) and spinal cord stimulation (SCS) is between 0.5% and 2.5%. Coagulation status is one of the factors that can predispose patients to the development of these complications. As a routine part of preoperative assessment, the authors obtain prothrombin time (PT), partial thromboplastin time (PTT), and platelet count. However, insurers often cover only PT/PTT laboratory tests if the patient is receiving warfarin/heparin. The authors aimed to examine their experience with abnormal coagulation parameters in patients who underwent neuromodulation. METHODS: Patients who underwent neuromodulation (SCS, DBS, or intrathecal pump implantation) over a 9-year period and had preoperative laboratory values available were included. The authors determined abnormal values on the basis of a clinical protocol utilized at their practice, which combined the normal ranges of the laboratory tests and clinical relevance. This protocol had cutoff values of 12 seconds and 39 seconds for PT and PTT, respectively, and < 120,000 platelets/μl. The authors identified risk factors for these abnormalities and described interventions. RESULTS: Of the 1767 patients who met the inclusion criteria, 136 had abnormal preoperative laboratory values. Five of these 136 patients had values that were misclassified as abnormal because they were within the normal ranges at the outside facility where they were tested. Fifty-one patients had laboratory values outside the ranges of our protocol, but the surgeons reviewed and approved these patients without further intervention. Of the remaining 80 patients, 8 had known coagulopathies and 24 were receiving warfarin/heparin. The remaining 48 patients were receiving other anticoagulant/antiplatelet medications. These included apixaban/rivaroxaban/dabigatran anticoagulants (n = 22; mean ± SD PT 13.7 ± 2.5 seconds) and aspirin/clopidogrel/other antiplatelet medications (n = 26; mean ± SD PT 14.4 ± 5.8 seconds). Eight new coagulopathies were identified and further investigated with hematological analysis. CONCLUSIONS: New anticoagulants and antiplatelet medications are not monitored with PT/PTT, but they affect coagulation status and laboratory values. Although platelet function tests aid in a subset of medications, it is more difficult to assess the coagulation status of patients receiving novel anticoagulants. PT/PTT may provide value preoperatively.
引用
- Hadanny A, Olmsted ZT, Marchese AM, et al. Preoperative evaluation of coagulation status in neuromodulation patients. J Neurosurg. 2021. PMID: 34826810. doi:10.3171/2021.8.JNS211509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。